A rat study tested prolonged saracatinib after standard countermeasures including midazolam. Favorable inflammation and seizure findings did not extend to every behavioral endpoint.
Rats received soman, atropine and an oxime, followed by delayed midazolam. Saracatinib or vehicle began afterward and continued through a prolonged treatment period.
The adjunct reduced some fear-like and motor abnormalities and altered spontaneous seizure severity. Histologic and inflammatory measures improved, but cognitive deficits measured at five to seven weeks were not mitigated.
Improved connectivity or pathology cannot be substituted for demonstrated cognitive recovery. The study compared an adjunctive strategy, not the independent effect of midazolam.
The long experimental course also differs from acute human rescue treatment. It cannot establish clinical efficacy, a human dosing schedule, or that midazolam caused residual deficits. The paper supports separating seizure control, neuroprotection, and functional recovery, with each outcome reported at its actual assessment time.
Original analysis of the supplied journal article, identified as PMC12326679.